Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) has received a consensus recommendation of “Buy” from the twelve research firms that are covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $37.00.
A number of brokerages have weighed in on RHHBY. Deutsche Bank upgraded Roche Holdings AG Basel from a “hold” rating to a “buy” rating in a research note on Thursday, June 20th. Liberum Capital lowered Roche Holdings AG Basel from a “buy” rating to a “hold” rating in a research note on Thursday, June 20th. UBS Group upgraded Roche Holdings AG Basel from a “neutral” rating to a “buy” rating in a research note on Friday, July 26th. Finally, Zacks Investment Research upgraded Roche Holdings AG Basel from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a research note on Tuesday, July 9th.
OTCMKTS RHHBY traded up $0.14 during trading on Friday, reaching $34.70. The company’s stock had a trading volume of 1,652,045 shares, compared to its average volume of 1,166,810. The stock has a market capitalization of $237.12 billion, a PE ratio of 14.96, a P/E/G ratio of 2.28 and a beta of 0.48. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.40 and a quick ratio of 1.11. The firm has a fifty day moving average of $34.31 and a 200 day moving average of $33.89. Roche Holdings AG Basel has a one year low of $25.10 and a one year high of $35.90.
About Roche Holdings AG Basel
Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases.
Recommended Story: What Factors Can Affect Return on Equity?
Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.